Physician profile
John S Hollowell
NPI 1083601520
$6,359.60
in general payments reported to CMS, 2019-2025
34 companies · $980 in 2025
The $980 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $351 · 2021: $658 · 2022: $849 · 2023: $1,026 · 2024: $1,324 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $713.87 | 2019-2024 | Xarelto |
| Amgen INC. | $706.83 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $590.32 | 2022-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $542.17 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $406.93 | 2019-2021 | |
| Scpharmaceuticals INC. | $387.43 | 2023-2025 | |
| Pfizer INC. | $268.99 | 2019-2025 | |
| Esperion Therapeutics, INC. | $242.08 | 2021-2025 | Nexletol |
| Astellas Pharma US INC | $217.83 | 2019-2023 | Lexiscan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.55 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $202.18 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $197.28 | 2019-2025 | Farxiga |
| Heartflow, INC. | $184.56 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $181.52 | 2024-2025 | Edarbyclor |
| E.R. Squibb & Sons, L.L.C. | $175.85 | 2020-2025 | Camzyos |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $149.09 | 2019-2022 | |
| Novo Nordisk INC | $131.71 | 2022-2025 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $104.59 | 2022-2025 | Onpattro, Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.58 | 2019-2024 | Lifevest |
| Arbor Pharmaceuticals, INC. | $95.85 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.84 | 2021-2025 | |
| Bridgebio Pharma, INC. | $62.79 | 2025 | Attruby |
| Itamar Medical INC | $60.76 | 2021-2023 | Watchpatone |
| Lexicon Pharmaceuticals, INC. | $56.17 | 2024 | |
| Gilead Sciences, INC. | $48.25 | 2019 | |
| Boston Scientific Corporation | $40.44 | 2019-2023 | Watchman Access System |
| Medtronic, INC. | $38.06 | 2025 | Linq II |
| Abbott Laboratories | $36.84 | 2025 | Cardiomems |
| Inspire Medical Systems, INC. | $36.44 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $31.43 | 2025 | Evkeeza |
| Impulse Dynamics (USA) INC. | $30.67 | 2025 | Optimizer |
| Cook Medical LLC | $19.38 | 2023 | Zilver Ptx |
| Tactile Systems Technology INC | $13.81 | 2021 | |
| Althera Pharmaceuticals LLC | $7.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hollowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.